Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,792 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,179)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07098338 | A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)(LIBRA) | recruiting | Phase 2 | 278 | AstraZenecaINDUSTRY | 12 | Jul 1, 2026 | clinicaltrials |
| NCT07609121 | Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable Stage III NSCLC | recruiting | Phase 2 | 160 | Sun Yat-sen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT07677787 | DLL3-Targeted PET/CT in Small Cell Lung Cancer | recruiting | N/A | 20 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT05136846 | Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer | recruiting | Phase 1 | 28 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT06162221 | Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | recruiting | Phase 1 / Phase 2 | 616 | Revolution Medicines, Inc.INDUSTRY | 13 | Jun 30, 2026 | clinicaltrials |
| NCT07652125 | RGL-270 + ICI in Advanced NSCLC | recruiting | N/A | 40 | Guangdong Association of Clinical TrialsOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT07327489 | Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)(ELEPHAS-05) | recruiting | — | 2,000 | ElephasINDUSTRY | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07458347 | A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation | recruiting | Phase 1 | 145 | Kestrel Therapeutics, Inc.OTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT07673861 | Clinical Utility of ctDNA in Detecting Resistance Mechanisms and Delivering Precision Medicine to Cancer Patients(CURTAIN) | recruiting | N/A | 100 | Royal Marsden NHS Foundation TrustOTHER | 1 | Jun 29, 2026 | clinicaltrials |
| NCT04614103 | Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | recruiting | Phase 2 | 170 | Iovance Biotherapeutics, Inc.INDUSTRY | 12 | Jun 26, 2026 | clinicaltrials |
| NCT06225427 | Gilteritinib for the Treatment of ALK NSCLC | recruiting | Phase 1 | 30 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06598306 | Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)(DeLLphi-308) | recruiting | Phase 1 | 220 | AmgenINDUSTRY | 10 | Jun 26, 2026 | clinicaltrials |
| NCT07149363 | Adjuvant Chemotherapy and Immunotherapy for Completely Resected Small Cell Lung Cancer | recruiting | Phase 2 | 65 | Alliance Foundation Trials, LLC.OTHER | 1 | Jun 26, 2026 | clinicaltrials |
| NCT06216301 | LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC(LUNAR-2) | recruiting | Phase 3 | 734 | NovoCure GmbHINDUSTRY | 16 | Jun 25, 2026 | clinicaltrials |
| NCT07131319 | SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | recruiting | Phase 2 / Phase 3 | 30 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07366658 | Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients(NEUK203-13) | recruiting | Phase 1 | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07652736 | A Study to Investigate Treatment Patterns and Effectiveness of Tislelizumab in European Patients With Resectable or Advanced Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC)(TITANS) | recruiting | — | 440 | BeOne MedicinesINDUSTRY | 1 | Jun 25, 2026 | clinicaltrials |
| NCT07668037 | Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy | recruiting | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 25, 2026 | clinicaltrials |
| NCT04806412 | Oncodrivers in Malignant Pleural Effusions Associated With Non-small Cell Lung Cancer: A Prospective Study. | recruiting | N/A | 100 | Naestved HospitalOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07337096 | Electro-Acupuncture in Lung cancER : EALER Study | recruiting | N/A | 424 | Guangzhou University of Traditional Chinese MedicineOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT07664579 | Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Coping Together Against Cancer | recruiting | — | 160 | City of Hope Medical CenterOTHER | 1 | Jun 24, 2026 | clinicaltrials |
| NCT04114136 | Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | recruiting | Phase 2 | 72 | Dan ZandbergOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06983899 | Exercise Training for the Improvement of Immune Activity and Treatment Outcomes During Immunotherapy for Non-small Cell Lung Cancer, BOOST Trial | recruiting | N/A | 100 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 23, 2026 | clinicaltrials |
| NCT07046923 | A Study of LY4175408 in Participants With Advanced Cancer | recruiting | Phase 1 | 240 | Eli Lilly and CompanyINDUSTRY | 6 | Jun 23, 2026 | clinicaltrials |
| NCT07636252 | Ex Vivo Drug Response Profiling and Outcome Prediction in Lung Adenocarcinoma | recruiting | — | 400 | Sheba Medical CenterOTHER_GOV | 1 | Jun 23, 2026 | clinicaltrials |
| NCT06545331 | Study of XB010 in Subjects With Solid Tumors | recruiting | Phase 1 | 396 | ExelixisINDUSTRY | 2 | Jun 22, 2026 | clinicaltrials |
| NCT07660094 | Aglatimagene Besadenovec + Prodrug and Pembrolizumab vs Docetaxel for Stage IV Non-Squamous NSCLC Progressing on Pembrolizumab (AURORA)(LuTK03) | recruiting | Phase 3 | 500 | Candel Therapeutics, Inc.INDUSTRY | 1 | Jun 22, 2026 | clinicaltrials |
| NCT06075524 | Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types | recruiting | — | 500 | Mayo ClinicOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT06971848 | Evaluation of Skin Tests in Biotherapy Allergies(ETCABIO) | recruiting | N/A | 70 | University Hospital, AngersOTHER_GOV | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07116057 | MOv19-BBz CAR T Cells in FRa+ Cancers | recruiting | Phase 1 | 10 | University of PennsylvaniaOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07153055 | Lurbinectedin With Osimertinib in Transformed Small Cell Lung Cancer(LOTS) | recruiting | Phase 1 / Phase 2 | 16 | Misty ShieldsOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07208773 | A Study of YL201 and Ivonescimab (AK112) in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 260 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07503808 | A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types | recruiting | Phase 1 | 150 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07508852 | 68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Peking University First HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07624487 | Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma | recruiting | Phase 2 | 50 | Taipei Medical University HospitalOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT07655622 | Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression(DUAL-THRUST) | recruiting | Phase 1 / Phase 2 | 45 | Second Affiliated Hospital of Nanchang UniversityOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT03199651 | Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer(BLCIO) | recruiting | N/A | 3,584 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04210492 | Dose-Deescalated 3-Fraction Stereotactic Body Radiotherapy For Centrally Located Lung Cancer | recruiting | Phase 1 / Phase 2 | 36 | Yale UniversityOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05570825 | SX-682 With Pembrolizumab for the Treatment of Metastatic or Recurrent Stage IIIC or IV Non-Small Cell Lung Cancer | recruiting | Phase 2 | 30 | University of WashingtonOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT05742607 | IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | recruiting | Phase 2 | 70 | Innate PharmaINDUSTRY | 5 | Jun 17, 2026 | clinicaltrials |
| NCT07164170 | A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Glecirasib | recruiting | Phase 2 | 86 | Abbisko Therapeutics Co, LtdINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07261631 | Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors | recruiting | Phase 1 | 180 | Novartis PharmaceuticalsINDUSTRY | 6 | Jun 17, 2026 | clinicaltrials |
| NCT07473128 | Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer | recruiting | Phase 3 | 120 | Pharmacosmos A/SINDUSTRY | 1 | Jun 17, 2026 | clinicaltrials |
| NCT07540572 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 | 160 | IDEAYA BiosciencesINDUSTRY | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07603856 | A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer(REVIVE) | recruiting | Phase 2 | 39 | University of ChicagoOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT07649629 | Impact of Liquid Biopsy on the Therapeutic Pathway for Lung Cancer: Advancing the Molecular Characterization of Patients With Advanced Lung Adenocarcinoma by Integrating Liquid Biopsy Into the Early Stages of the Diagnostic and Therapeutic Pathway(INNOVA-LUNG) | recruiting | — | 70 | Regina Elena Cancer InstituteOTHER | 1 | Jun 16, 2026 | clinicaltrials |
| NCT05257551 | Tempus Small Cell Lung Cancer Observational Study (Sculptor) | recruiting | — | 200 | Tempus AIINDUSTRY | 1 | Jun 15, 2026 | clinicaltrials |
| NCT05589818 | Pembrolizumab for Advanced NSCLC and PS 2-3 | recruiting | Phase 2 | 45 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Jun 15, 2026 | clinicaltrials |
| NCT06213532 | CONNECTing to LungCare | recruiting | N/A | 152 | University of California, San FranciscoOTHER | 1 | Jun 15, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jul 1, 2026source: clinicaltrials